Shanghai RAAS Blood Products Co Ltd Class A (002252) - Total Assets
Based on the latest financial reports, Shanghai RAAS Blood Products Co Ltd Class A (002252) holds total assets worth CN¥37.98 Billion CNY (≈ $5.56 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shanghai RAAS Blood Products Co Ltd Class A - Total Assets Trend (2005–2025)
This chart illustrates how Shanghai RAAS Blood Products Co Ltd Class A's total assets have evolved over time, based on quarterly financial data. Also see market cap of Shanghai RAAS Blood Products Co Ltd Clas for the company's overall valuation and market capitalisation.
Shanghai RAAS Blood Products Co Ltd Class A - Asset Composition Analysis
Current Asset Composition (December 2025)
Shanghai RAAS Blood Products Co Ltd Class A's total assets of CN¥37.98 Billion consist of 26.3% current assets and 73.7% non-current assets. Review Shanghai RAAS Blood Products Co Ltd Clas (002252) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 3.6% |
| Accounts Receivable | CN¥2.36 Billion | 6.3% |
| Inventory | CN¥5.37 Billion | 14.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥732.55 Million | 1.9% |
| Goodwill | CN¥8.20 Billion | 21.7% |
Asset Composition Trend (2005–2025)
This chart illustrates how Shanghai RAAS Blood Products Co Ltd Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Shanghai RAAS Blood Products Co Ltd Clas for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai RAAS Blood Products Co Ltd Class A's current assets represent 26.3% of total assets in 2025, a decrease from 73.8% in 2005.
- Cash Position: Cash and equivalents constituted 3.6% of total assets in 2025, down from 6.8% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 21.7% of total assets.
Shanghai RAAS Blood Products Co Ltd Class A Competitors by Total Assets
Key competitors of Shanghai RAAS Blood Products Co Ltd Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
PYC Therapeutics Ltd
AU:PYC
|
Australia | AU$183.28 Million |
Shanghai RAAS Blood Products Co Ltd Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.73 | 5.01 | 7.74 |
| Quick Ratio | 1.74 | 3.08 | 4.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥7.61 Billion | CN¥8.55 Billion | CN¥5.15 Billion |
Shanghai RAAS Blood Products Co Ltd Class A - Advanced Valuation Insights
This section examines the relationship between Shanghai RAAS Blood Products Co Ltd Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.01 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | 12.4% |
| Total Assets | CN¥37.80 Billion |
| Market Capitalization | $4.74 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai RAAS Blood Products Co Ltd Class A's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Shanghai RAAS Blood Products Co Ltd Class A's assets grew by 12.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Shanghai RAAS Blood Products Co Ltd Class A (2005–2025)
The table below shows the annual total assets of Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥37.80 Billion ≈ $5.53 Billion |
+12.41% |
| 2024-12-31 | CN¥33.63 Billion ≈ $4.92 Billion |
+5.33% |
| 2023-12-31 | CN¥31.93 Billion ≈ $4.67 Billion |
+4.83% |
| 2022-12-31 | CN¥30.46 Billion ≈ $4.46 Billion |
+11.83% |
| 2021-12-31 | CN¥27.24 Billion ≈ $3.99 Billion |
+6.84% |
| 2020-12-31 | CN¥25.49 Billion ≈ $3.73 Billion |
+115.08% |
| 2019-12-31 | CN¥11.85 Billion ≈ $1.73 Billion |
+4.01% |
| 2018-12-31 | CN¥11.40 Billion ≈ $1.67 Billion |
-21.16% |
| 2017-12-31 | CN¥14.46 Billion ≈ $2.12 Billion |
+9.30% |
| 2016-12-31 | CN¥13.23 Billion ≈ $1.94 Billion |
+14.45% |
| 2015-12-31 | CN¥11.56 Billion ≈ $1.69 Billion |
+23.21% |
| 2014-12-31 | CN¥9.38 Billion ≈ $1.37 Billion |
+495.47% |
| 2013-12-31 | CN¥1.58 Billion ≈ $230.49 Million |
+30.36% |
| 2012-12-31 | CN¥1.21 Billion ≈ $176.81 Million |
+19.69% |
| 2011-12-31 | CN¥1.01 Billion ≈ $147.73 Million |
+8.51% |
| 2010-12-31 | CN¥930.33 Million ≈ $136.14 Million |
+12.74% |
| 2009-12-31 | CN¥825.22 Million ≈ $120.76 Million |
-0.72% |
| 2008-12-31 | CN¥831.19 Million ≈ $121.63 Million |
+171.15% |
| 2007-12-31 | CN¥306.54 Million ≈ $44.86 Million |
-5.73% |
| 2006-12-31 | CN¥325.16 Million ≈ $47.58 Million |
-2.54% |
| 2005-12-31 | CN¥333.63 Million ≈ $48.82 Million |
-- |
About Shanghai RAAS Blood Products Co Ltd Class A
Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally. The company offers ALBURAAS, which is albumin prepared from human plasma; GAMARAAS, a human immunoglobulin product for intravenous injections; HEMORAAS, a human coagulation factor VIII product; PROTHORAAS, a human prothrombin complex; FIBRORAAS, a human fibrinoge… Read more